The Estonian Genome Center aims to introduce genomic medicine via the country's online medical data infrastructure, according to Andres Metspalu, its director.
With exome sequencing data on nearly 10,000 individuals with or without early-onset myocardial infarction, researchers narrowed in on two genes prone to rare mutations in those at enhanced heart attack risk.
A retrospective study of patients seen over two years at the emergency department of Sweden's Karolinska University Hospital has demonstrated that using a very low cutoff point when measuring the protein biomarker cardiac troponin T could accurately rule out heart attack in a lar
NEW YORK (GenomeWeb Daily News) – A certain polymorphism in the stress-linked serotonin 2C receptor gene is linked to an increased risk of cardiovascular disease morbidity and mortality, researchers led by Duke University's Redford Williams
Clinical researchers at Beth Israel Deaconess Medical Center and Harvard Medical School have teamed up with RainDance Technologies to explore the use of RainDance's picodroplet-based digital PCR platform to measure microRNA biomarkers in the blood of patients undergoing various c
On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (
NEW YORK (GenomeWeb News) – Aviir today announced the completion of a $10 million tranche, completing a financing round started in December 2011 that raised a total of $30 million.
Bolstered by a recent $10 million financing round and a 19-country distribution pact, Irvine, Calif.-based biotech firm Aviir is pushing its MIRISK VP protein biomarker test into the increasingly crowded cardiac risk assessment market.
NEW YORK (GenomeWeb News) – Partners & Partners will be the sole distributor of Aviir's tests and technologies in 19 countries in the Middle East and North Africa as part of a deal announced today.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
